8-K: Iterum Therapeutics Resubmits New Drug Application for Oral Sulopenem to FDA

Iterum Therapeutics has resubmitted its New Drug Application to the FDA for oral sulopenem, a potential new treatment for uncomplicated urinary tract infections in adult women.

Summary

• Iterum Therapeutics has resubmitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for oral sulopenem, intended for the treatment of uncomplicated urinary tract infections (uUTIs) in adult women.
• The resubmission includes data from the REASSURE, SURE 1, SURE 2, and SURE 3 phase 3 clinical trials.
• The company expects the FDA to complete its review within six months of the resubmission, potentially leading to approval in early Q4 2024.
• Oral sulopenem, if approved, would be the first oral penem antibiotic in the U.S. and the second new oral treatment for uUTIs in over 25 years.
• The company estimates that 40 million uUTIs occur each year in the U.S.

Sentiment

Score: 7

Explanation: The document is generally positive due to the resubmission of the NDA and the potential for FDA approval. However, there are risks and uncertainties mentioned, which temper the overall sentiment.

Positives

• The resubmission of the NDA is a significant step forward for bringing a new antibiotic to market.
• Clinical trials have shown oral sulopenem to be effective and well-tolerated.
• Oral sulopenem has demonstrated superiority over Augmentin and ciprofloxacin in certain patient populations.
• The potential approval of oral sulopenem would provide a new treatment option for a common infection.
• The drug has received Qualified Infectious Disease Product (QIDP) and Fast Track designations.

Risks

• The FDA may not approve the NDA despite the resubmission.
• The company's cash on hand may not be sufficient to fund ongoing operations.
• There are risks associated with the company's ability to maintain its listing on the Nasdaq Capital Market.
• The company faces uncertainties related to the outcome of strategic alternatives it is pursuing.
• The company's actual results may differ materially from forward-looking statements due to various factors.

Future Outlook

The company anticipates potential FDA approval of oral sulopenem in early Q4 2024, pending a successful review of the resubmitted NDA. The company is also pursuing strategic alternatives to address its financial situation.

Management Comments

• Corey Fishman, Chief Executive Officer, stated that the resubmission is a significant step forward in bringing a new antibiotic to the market.
• Corey Fishman noted that the availability of oral sulopenem would provide physicians and patients with the benefits of penem antibiotics, which have previously only been available in IV formulations.

Industry Context

The resubmission of the NDA for oral sulopenem addresses a critical need for new antibiotics, particularly for multi-drug resistant pathogens. The potential approval of oral sulopenem would provide a new treatment option for uUTIs, a common infection, and could be a significant advancement in the field of infectious disease treatment.

Comparison to Industry Standards

• The company's clinical trials compared oral sulopenem to Augmentin and ciprofloxacin, which are commonly used antibiotics for uUTIs.
• The results showed that oral sulopenem was non-inferior to Augmentin and superior to ciprofloxacin in certain patient populations.
• The potential approval of oral sulopenem would provide a new option in a market that has seen limited innovation in recent years.
• The company is aiming to address the growing problem of antibiotic resistance, which is a major concern in the healthcare industry.

Stakeholder Impact

• Shareholders may see a positive impact if the drug is approved.
• Patients would benefit from a new treatment option for uUTIs.
• Physicians would have a new tool to combat antibiotic resistance.
• The company's employees would be impacted by the success or failure of the NDA.

Next Steps

• The company will work with the FDA through the review process.
• The company anticipates a potential FDA decision on the NDA in early Q4 2024.

Key Dates

Keywords

sulopenem, urinary tract infections, uUTIs, FDA, New Drug Application, antibiotic, penem, clinical trials, REASSURE, SURE, Iterum Therapeutics